Vergent Bioscience is a clinical-stage biotechnology company that is helping surgeons realize the full potential of minimally invasive and robotic-assisted surgery by significantly improving the visibility of tumors.

Vergent’s lead compound, VGT-309, is a tumor-targeted fluorescent imaging agent intentionally designed to enable surgeons to see previously undetected or difficult-to-find tumors during surgery in real-time, ensuring all tumor tissue is removed. We are first evaluating VGT-309 in lung cancer, with the potential to expand its application to a wide range of solid tumors.

Our approach directly addresses the clinical need and market opportunity for advanced visualization in open, laparoscopic, and robotic-assisted surgical procedures.

Vergent Bioscience

Approximately every 2.5 minutes, someone in the U.S. is diagnosed with lung cancer. Throughout the year, and during #LungCancerAwarenessMonth, we join the community in raising awareness of #LungCancer as one of the most common and deadly cancers in the U.S.
 
Learn more about our work in this space: https://lnkd.in/eiC8Nesy

Earlier this month we presented new clinical data on VGT-309, our tumor-targeted imaging agent for cancer in the lung. See the highlights below and our full study results here: https://lnkd.in/eEctafUm
 
#VergentBioNews #tumorvisualization #innovation #lungcancer

Earlier this week we presented new clinical data on VGT-309, our tumor-targeted imaging agent for cancer in the lung. Learn more about VGT-309 below and read the results of our recent study on our website: https://lnkd.in/eiC8Nesy 

#VergentBioNews #tumorvisualization #innovation #lungcancer

Today we presented new data on the clinical performance of VGT-309 at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer. #WCLC23
 
The study provides compelling evidence that VGT-309 has a high affinity for malignant tissue in the lung, increasing the potential that surgeons can identify all tumor tissue during surgery.
 
Read more: https://lnkd.in/eEctafUm
#VergentBioNews #tumorvisualization #innovation #lungcancer

On Monday, September 11, we will present data from a Phase 2 study of VGT-309, our tumor-activated fluorescent molecule for the intraoperative identification of #lungcancer, at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer. #WCLC23
 
Follow our page to stay updated or stop by to hear our presentation live if you are attending! #VergentBioNews

We will present Phase 2 clinical data for VGT-309 at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer in Singapore on September 11. 
 
Researchers will share findings from the first surgical study using our novel, tumor-targeted fluorescent imaging agent designed to make lung cancer surgery more successful by improving the intraoperative visualization of tumors.
 
Read the press release: https://lnkd.in/eTcEjNu5 
 
#VergentBioNews #WCLC23 #tumorvisualization #innovation #lungcancer

Vergent Bioscience is growing! We are looking for a Field Clinical Operations Specialist to provide support for thoracic surgery clinical trial sites. Vergent is a biotech company focusing the on development of tumor-targeted molecular imaging agents for cancer surgery. 

Please reach out to Andrea Simpson if you are interested in learning more about this position.

Vergent Bioscience Awarded National Cancer Institute Phase 2 Grant to Advance Clinical Development of VGT-309 in Lung Cancer.
 
#VergentBiosNews #LungCancer #TumorVisualization #Innovation

Nearly $2MM Small Business Innovation Research grant will support the study of our targeted fluorescent imaging agent designed to improve tumor visualization during minimally invasive and robotic-assisted surgical procedures.
 
Read the announcement: http://bit.ly/3F7Tzpn 
 
#VergentBioNews #tumorvisualization #innovation

Vergent Bioscience is a clinical-stage biotechnology company that is helping surgeons realize the full potential of minimally invasive and robotic-assisted surgery by improving the visibility of tumors. Their lead compound, VGT-309, is a tumor-targeted fluorescent imaging agent designed to enable surgeons to see previously undetected or difficult-to-find tumors during surgery in real time, ensuring all tumor tissue is removed. They are first evaluating VGT-309 in lung cancer, with the potential to expand its application to a wide range of solid tumors.

COM:VERGENTBIO

Vergent Bioscience

Filings Not Available